
Zach Walsh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10437111/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cannabis for therapeutic purposes: Patient characteristics, access, and reasons for use. International Journal of Drug Policy, 2013, 24, 511-516.	3.3	257
2	MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology, 2019, 236, 2735-2745.	3.1	240
3	Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. International Journal of Drug Policy, 2017, 42, 30-35.	3.3	202
4	Medical cannabis and mental health: A guided systematic review. Clinical Psychology Review, 2017, 51, 15-29.	11.4	168
5	Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. Drug and Alcohol Review, 2016, 35, 326-333.	2.1	124
6	Experiences of Kratom Users: A Qualitative Analysis. Journal of Psychoactive Drugs, 2015, 47, 360-367.	1.7	110
7	Kratom use and mental health: A systematic review. Drug and Alcohol Dependence, 2018, 183, 134-140.	3.2	104
8	Psychopathy and Instrumental Violence: Facet Level Relationships. Journal of Personality Disorders, 2009, 23, 416-424.	1.4	83
9	Beyond Social Deviance: Substance Use Disorders and the Dimensions of Psychopathy. Journal of Personality Disorders, 2007, 21, 273-288.	1.4	78
10	Domestic violence and psychopathic traits: distinguishing the antisocial batterer from other antisocial offenders. Aggressive Behavior, 2007, 33, 253-260.	2.4	74
11	Barriers to access for Canadians who use cannabis for therapeutic purposes. International Journal of Drug Policy, 2014, 25, 691-699.	3.3	73
12	The Evidentiary Introduction of Psychopathy Checklist-Revised Assessed Psychopathy in U.S. Courts: Extent and Appropriateness Law and Human Behavior, 2006, 30, 493-507.	0.7	66
13	Subtypes of partner violence perpetrators among male and female psychiatric patients Journal of Abnormal Psychology, 2010, 119, 563-574.	1.9	66
14	The relationships of classic psychedelic use with criminal behavior in the United States adult population. Journal of Psychopharmacology, 2018, 32, 37-48.	4.0	61
15	Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials. Arthritis Care and Research, 2016, 68, 681-688.	3.4	60
16	Frequency of cannabis and illicit opioid use among people who use drugs and report chronic pain: A longitudinal analysis. PLoS Medicine, 2019, 16, e1002967.	8.4	56
17	Psychopathy and violence: The importance of factor level interactions Psychological Assessment, 2008, 20, 114-120.	1.5	49
18	Psychopathy and Axis I psychiatric disorders among criminal offenders: relationships to impulsive and proactive aggression. Aggressive Behavior, 2010, 36, 45-53.	2.4	48

ZACH WALSH

#	Article	IF	CITATIONS
19	Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints. BMC Musculoskeletal Disorders, 2014, 15, 258.	1.9	48
20	Psychopathy and Risk Taking Among Jailed Inmates. Criminal Justice and Behavior, 2010, 37, 439-452.	1.8	46
21	Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use. Journal of Psychopharmacology, 2016, 30, 601-607.	4.0	46
22	Psychedelics and the new behaviourism: considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy. International Review of Psychiatry, 2018, 30, 343-349.	2.8	45
23	Cannabis Significantly Reduces the Use of Prescription Opioids and Improves Quality of Life in Authorized Patients: Results of a Large Prospective Study. Pain Medicine, 2021, 22, 727-739.	1.9	45
24	Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open, 2022, 8, e19.	0.7	45
25	Psychopathy, IQ, and Violence in European American and African American County Jail Inmates Journal of Consulting and Clinical Psychology, 2004, 72, 1165-1169.	2.0	43
26	Impulsive versus premeditated aggression in the prediction of violent criminal recidivism. Aggressive Behavior, 2015, 41, 346-352.	2.4	41
27	Are dispensaries indispensable? Patient experiences of access to cannabis from medical cannabis dispensaries in Canada. International Journal of Drug Policy, 2017, 47, 1-8.	3.3	36
28	Psychedelic use and intimate partner violence: The role of emotion regulation. Journal of Psychopharmacology, 2018, 32, 749-755.	4.0	35
29	Cannabis education needs assessment among Canadian physicians-in-training. Complementary Therapies in Medicine, 2020, 49, 102328.	2.7	35
30	The Impact of Depressive Symptoms on the Efficacy of Naltrexone in Smoking Cessation. Journal of Addictive Diseases, 2008, 27, 65-72.	1.3	33
31	Psychopathy and violent crime: A prospective study of the influence of socioeconomic status and ethnicity Law and Human Behavior, 2007, 31, 209-229.	0.7	30
32	Characterizing motivations for cannabis use in a cohort of people who use illicit drugs: A latent class analysis. PLoS ONE, 2020, 15, e0233463.	2.5	25
33	Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Scientific Reports, 2021, 11, 22479.	3.3	25
34	Psychopathy and criminal violence: The moderating effect of ethnicity Law and Human Behavior, 2013, 37, 303-311.	0.7	23
35	Self-Reported Childhood Physical Abuse and Perpetration of Intimate Partner Violence. Criminal Justice and Behavior, 2012, 39, 910-922.	1.8	22
36	The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women. Journal of Psychopharmacology, 2018, 32, 1385-1391.	4.0	22

ZACH WALSH

#	Article	IF	CITATIONS
37	Childhood abuse and harmful substance use among criminal offenders. Addictive Behaviors, 2011, 36, 1205-1212.	3.0	21
38	The therapeutic potential of kratom. Addiction, 2018, 113, 1951-1953.	3.3	21
39	Guidelines for public health and safety metrics to evaluate the potential harms and benefits of cannabis regulation in Canada. Drug and Alcohol Review, 2019, 38, 606-621.	2.1	21
40	Childhood Sexual Abuse and the Perpetration of Violence: The Moderating Role of Gender. Journal of Aggression, Maltreatment and Trauma, 2015, 24, 381-399.	1.4	20
41	A paradigm change to inform fibromyalgia research priorities by engaging patients and health care professionals. Canadian Journal of Pain, 2017, 1, 137-147.	1.7	19
42	Psychopathy, self-identified race/ethnicity, and nonviolent recidivism: A longitudinal study Law and Human Behavior, 2018, 42, 531-544.	0.7	18
43	Socioeconomic-Status and Mental Health in a Personality Disorder Sample: The Importance of Neighborhood Factors. Journal of Personality Disorders, 2013, 27, 820-831.	1.4	17
44	Psychopathy Subtypes Among African American County Jail Inmates. Criminal Justice and Behavior, 2008, 35, 1484-1499.	1.8	16
45	The Potential for Kratom as an Antidepressant and Antipsychotic. Yale Journal of Biology and Medicine, 2020, 93, 283-289.	0.2	16
46	Reactive and Proactive Aggression and Suicide Attempts Among Criminal Offenders. Criminal Justice and Behavior, 2014, 41, 337-344.	1.8	15
47	Does cannabis use modify the effect of post-traumatic stress disorder on severe depression and suicidal ideation? Evidence from a population-based cross-sectional study of Canadians. Journal of Psychopharmacology, 2020, 34, 181-188.	4.0	15
48	Exploring the self-reported motivations of kratom (<i>Mitragyna speciosa</i> Korth.) use: a cross-sectional investigation. American Journal of Drug and Alcohol Abuse, 2022, 48, 433-444.	2.1	15
49	Psychopathy and violence: increasing specificity. Netherlands Journal of Psychology, 2007, 63, 125-132.	0.5	14
50	Psychopathy, alcohol use, and intimate partner violence: Evidence from two samples Law and Human Behavior, 2016, 40, 517-523.	0.7	12
51	Classic Psychedelic Use and Mechanisms of Mental Health: Exploring the Mediating Roles of Spirituality and Emotion Processing on Symptoms of Anxiety, Depressed Mood, and Disordered Eating in a Community Sample. Journal of Humanistic Psychology, 0, , 002216782110480.	2.1	12
52	Reductions in alcohol use following medical cannabis initiation: results from a large cross-sectional survey of medical cannabis patients in Canada. International Journal of Drug Policy, 2020, 86, 102963.	3.3	11
53	Attentional Bias in Psychopathy. International Journal of Offender Therapy and Comparative Criminology, 2016, 60, 1344-1357.	1.2	9
54	Canadian clinical practice guidelines for the use of plant-based cannabis and cannabinoid-based products in the management of chronic non-cancer pain and co-occurring conditions: protocol for a systematic literature review. BMJ Open, 2020, 10, e036114.	1.9	9

ZACH WALSH

#	Article	IF	CITATIONS
55	The Cannabis-Dependent Relationship Between Methadone Treatment Dose and Illicit Opioid Use in a Community-Based Cohort of People Who Use Drugs. Cannabis and Cannabinoid Research, 2023, 8, 155-165.	2.9	8
56	A longitudinal analysis of cannabis use and mental health symptoms among gay, bisexual, and other men who have sex with men in Vancouver, Canada. Journal of Affective Disorders, 2019, 247, 125-133.	4.1	7
57	Fantastic and uninviting behavior: psychopathy, alcohol, and violence. Journal of Aggression, Conflict and Peace Research, 2018, 10, 210-222.	0.6	6
58	Self-reported reductions in tobacco and nicotine use following medical cannabis initiation: Results from a cross-sectional survey of authorized medical cannabis patients in Canada. Journal of Substance Abuse Treatment, 2021, 130, 108481.	2.8	6
59	Facial affect recognition in college students with psychopathic traits: A comparison using tests matched in discriminating power. Journal of Research in Personality, 2019, 78, 52-60.	1.7	5
60	No Evidence of Altered Reactivity to Experimentally Induced Pain Among Regular Cannabis Users. Clinical Journal of Pain, 2020, 36, 589-593.	1.9	5
61	Current and Future Potential Impact of COVID-19 on Kratom (Mitragyna speciosa Korth.) Supply and Use. Frontiers in Psychiatry, 2020, 11, 574483.	2.6	5
62	Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems. Frontiers in Psychiatry, 2021, 12, 716593.	2.6	5
63	Evaluation of a cognitiveâ€behavioral intervention for high―and mediumâ€risk probationers. Behavioral Sciences and the Law, 2019, 37, 329-341.	0.8	4
64	Employing matched tests to assess facial affect recognition anomalies in offenders high in psychopathy. Personality and Individual Differences, 2020, 160, 109945.	2.9	3
65	Physician Communication and Perceived Stigma in Prenatal Cannabis Use. Journal of Psychoactive Drugs, 2023, 55, 290-298.	1.7	3
66	The Medical Cannabis Standards Engagement Evaluation and Dissemination (SEED) project: A community-based research approach to self-regulating medical cannabis dispensaries in Canada. International Journal of Drug Policy, 2020, 78, 102708.	3.3	1
67	The impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients. Journal of Cannabis Research, 2021, 3, 34.	3.2	1
68	Personality and life events in a personality disorder sample Personality Disorders: Theory, Research, and Treatment, 2017, 8, 376-382.	1.3	0
69	A crude approach to evaluating cannabis legalization. Cmaj, 2019, 191, E109-E109.	2.0	0
70	Cannabis Epistemology and the Case-Series Design: An Invited Commentary on a Case Series and a Dismissive Response. Journal of Alternative and Complementary Medicine, 2020, 26, 259-260.	2.1	0
71	The relationship between psychopathy and conviction rates: Examining the conviction-to-charge ratio. Psychology, Crime and Law, 0, , 1-27.	1.0	0